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A general problem in the evaluation of superficial bladder tumours
(Ta, T1) is the tendency to underdiagnose the extent of the disease.
Treatment decisions for individual patients with superficial
bladder tumour have been based on tumour grade. Although
intravesical chemotherapy and Bacillus Calmette-Guerin (BCG)
immunotherapy reduce disease in superficial bladder tumours
(Vegt et al, 1995), intravesical therapies fail to influence the long-
term course of superficial disease (Lamm et al, 1995).
Furthermore, it has been well known that the majority of super-
ficial bladder tumours recur, and a certain percentage of these will
be at a higher stage and progress (Loening et al, 1980; Heney et al,
1983). On the other hand, systemic chemotherapy using
methotrexate, vinblastine, adriamycin and cisplatinum (M-VAC)
has become widespread as a promising regimen for invasive
bladder tumours because of its improved effectiveness over
previous chemotherapeutic regimens (Sternberg et al, 1985; Geller
et al, 1991). Nevertheless, the prognosis is still poorer than might
be expected (Conner et al, 1990). Therefore, elucidation of the
underlying molecular mechanisms for recurrence and progression
from superficial to invasive disease may offer new treatment
strategies. 
The malignant transformation of the tumour cell is determined
by a sequence of genetic alterations, in which alterations of cell
cycle-regulating genes are evolving as important factors of
promoting tumour development (Hunter and Pines, 1994). In the
mammalian cell cycle, the G1/S restriction point is thought to be
the most important checkpoint. p27Kip1 (p27) is a negative
cell cycle-regulating gene that belongs to the p21WAF/CIP1 cyclin-
dependent kinase inhibitor family. p27 redistributes from the
cyclin D1-Cdk4/6 complex of mid G1 to the cyclin E-Cdk2
complex regulating late G1 (Toyoshima and Hunter, 1994). p27
plays a central role in the transition from late G1 to S phase and
activation of the cyclin E-Cdk2 complex is the rate-limiting event
for transition into S phase (Steeg and Abrams, 1997). 
Regulation of p27 occurs at the post-translational level.
Although mutations in the p27 gene are rare in human cancers,
decreased p27 protein levels have a negative prognostic impact in
breast (Catzavelos et al, 1997; Porter et al, 1997), lung (Esposito
et al, 1997), gastric (Mori et al, 1997), colorectal (Loda et al,
1997), ovarian (Masciullo et al, 1999) and prostate cancer
(Tsihlias et al, 1998; Yang et al, 1998; Kuczyk et al, 1999). We
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have previously reported that low p27 protein levels and a high Ki-
67 index were associated with unfavourable prognosis in upper
urinary tract cancer (Kamai et al, 2000). Increased expression of
cyclin E is associated with shortened survival in breast cancer
(Keyomarsi et al, 1997; Porter et al, 1997). In bladder cancer,
reduced protein levels of p27 and cyclin E correlate with early
recurrence and shortened survival (Del Pizzo et al, 1999; Lee et al,
1999; Sgambato et al, 1999). 
To date, there are no available data regarding alterations in these
protein levels during the progression from superficial to invasive
bladder cancer. Therefore, additional studies are required to eluci-
date the relationship between p27 and other proteins implicated in
G1/S transition (e.g. cyclin E) and in S-phase (e.g. Ki-67) in devel-
opment of the bladder cancer. At first, we compared protein levels
of p27, cyclin E and Ki-67 in tumour cells using immunohisto-
chemical staining with the clinicopathological features of the
patients to assess their role in predicting survival. We also
analysed these protein levels at recurrence and with progression
from superficial to invasive disease to examine the biological
behaviour of bladder cancer. We discuss the implications of the
findings. 
MATERIALS AND METHODS 
Patients 
Biopsy specimens of bladder cancers obtained between 1987 and
1997 from 145 consecutive Japanese patients (101 men, 44
women), 54 to 97 years old (mean age 76.1 years), with newly
diagnosed primary transitional cell carcinoma (TCC) of the
bladder were examined. All patients routinely had imaging studies
(CT and/or MRI) prior to surgery for standard staging. Follow-up
ranged from 3 to 124 months (median follow-up, 50 months).
Surgical specimens were obtained at the first operation before
receiving any therapy. Some patients received adjuvant therapies
after the first operation. Generally, intravesical mitomycin C,
doxorubicin, and/or BCG was used in superficial tumours after the
initial therapy or during follow-up, or at both times when the
tumour was high grade or had a high likelihood of recurrence. 
M-VAC chemotherapy was used in high-grade invasive tumours.
Surgical specimens were fixed in buffered formalin (pH 7.0),
embedded in paraffin, sectioned at 5 mm, and stained with haema-
toxylin and eosin. The grade and stage were classified according to
the criteria of the TNM staging system (Sobin et al, 1997). 
Immunostaining 
Immunohistochemical staining was performed with anti-p27Kip1
monoclonal antibody (Transduction Laboratories, Lexington,
KY), anti-cyclin E polyclonal antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) and anti-Ki-67 monoclonal anti-
body, MIB-1 (Medical and Biological Laboratories, Nagoya,
Japan) using the immunoperoxidase technique and microwave
treatment of tissue sections in citrate buffer as described previ-
ously (Catzavelos et al, 1997; Loda et al, 1997; Kamai et al, 2000).
Negative controls using irrelevant mouse immunoglobulin
revealed no staining. Positive controls for p27 and cyclin E
consisted of paraffin sections of breast cancer cells (Catzavelos 
et al, 1997; Porter et al, 1997). Tumour nuclei that showed dark
brown granular staining with anti-Ki-67 were considered positive
(Kamai et al, 2000). In each case, p27, cyclin E, and Ki-67 scoring
was determined by examining 1000 cancer cells in 3 to 7 
slide sections in each of 5 to 10 microscopic fields under ´400
magnification. The labelling index was expressed as the ratio of
total labelled cells to the total number of tumour cells counted
(Catzavelos et al, 1997; Loda et al, 1997; Del Pizzo et al, 1999;
Kamai et al, 2000). Scoring was done by 3 of the authors indepen-
dently (TK, HA and YI). The labelling index threshold was based
on methods described previously (Catzavelos et al, 1997; Loda et
al, 1997; Del Pizzo et al, 1999; Kamai et al, 2000). p27 scoring
was classified into 2 categories of tumour cell nuclear staining;
low (<50%) and high (>50%) (Catzavelos et al, 1997; Loda et al,
1997; Kamai et al, 2000), cyclin E; low (<30%) and high (>30%)
(Del Pizzo et al, 1999) and Ki-67 labelling; low (<30%) and high
(>30%) (Kamai et al, 2000). 
Statistical analysis 
The chi-square test and Fisher’s exact test were used for compari-
sons between p27 staining and cyclin E scoring and for prognostic
variables including histological grade, pathological stage, lymph
node metastasis and tumour proliferation by the Ki-67 index. p27
and cyclin E scoring and prognostic variables were analysed for
disease-free and overall survival by the Cox proportional hazards
model using univariate and multivariate analysis. The Kaplan–
Meier method was used to estimate survival as a function of
time, and survival differences were analysed by the log-rank test.
P values less than 0.05 were considered significant. Data were
analysed with commercial software. 
RESULTS 
Relationship of p27 and cyclin E protein levels with
clinical characteristics 
Cells showing positive reactions for anti-p27Kip1, anti-cyclin E and
MIB-1 showed predominant immunostaining in the nucleus. The
normal urothelium showed a uniformly strong positive reaction
with anti-p27Kip1 and a very weakly positive reaction for MIB-1.
Although the overall number and intensity of cyclin E immuno-
reactive cells was not as high as for p27Kip1, normal urothelium
demonstrated uniformly abundant staining with anti-cyclin E.
Expression of p27, cyclin E and Ki-67 was observed in 121 of 145
patients (83.4%), 107/145 (73.8%), and all patients, respectively.
Tumour cells showed heterogeneous immunostaining: moderate to
negative levels of immunoreactivity for p27 and cyclin E (Figures
1 and 2) and moderate to strong levels for Ki-67. The immunohis-
tochemical analysis in relation to tumour characteristics are
summarized in Table 1. Decreased protein levels of p27 correlated
with poorly differentiated grade (P = 0.0006), higher stage (P =
0.0019), lymph node involvement (P = 0.0002), lower cyclin E
staining (P = 0.0302), and higher tumour proliferation (P =
0.0306). Decreased protein levels of cyclin E were associated with
poorly differentiated grade (P = 0.0187), higher stage (P = 0.0387)
and higher tumour proliferation (P = 0.0002), but not with lymph
node disease (P = 0.6143). The higher Ki-67 index correlated with
poorly differentiated grade (P < 0.0001), higher stage (P < 0.0001)
and lymph node involvement (P < 0.0001). 
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Univariate disease-free survival analysis revealed that p27
(P < 0.0001, relative risk [RR] = 4.369), Ki-67 (P < 0.0001, RR =
3.876), stage (P < 0.0001, RR = 1.826), cyclin E (P = 0.0004,
RR = 2.589), grade (P = 0.0005, RR = 1.878), and lymph node
disease (P = 0.0363, RR = 2.469) had significant survival effects
(Table 2). p27 and Ki-67 were independent predictors of a short-
ened disease-free survival (P < 0.0001, RR = 3.879 and P =
0.0031, RR = 2.914, respectively) by multivariate analysis. 
With regard to overall survival, univariate analysis showed that
p27 (P < 0.0001, RR = 12.878), cyclin E (P < 0.0001, RR = 6.346),
Ki-67 (P < 0.0001, RR = 23.352), stage (P < 0.0001, RR = 3.484),
grade (P < 0.0001, RR = 3.724), and lymph node involvement (P =
0.0019, RR = 4.624) were significant. On multivariate analysis,
Ki-67 (P = 0.0003, RR = 12.971), cyclin E (P = 0.0009, RR =
7.749), stage (P = 0.0011, RR = 2.640), and p27 (P = 0.0017, RR =
10.434) were independent prognostic factors for overall survival
(Table 2). 
Kaplan–Meier plots of survival rates in patients with low
versus high p27 staining showed that low staining of p27 corre-
lated with shortened disease-free and overall survival (P <
0.0001 and P < 0.0001, respectively, Figure 3A, C). Low
staining of cyclin E was associated with early recurrence and a
lower overall survival (P = 0.0003, P < 0.0001, respectively,
Figure 3B, D). The prognosis of patients with a high Ki-67
index was poor for both disease-free and overall survival in
comparison to those with a low Ki-67 index (P < 0.0001, P <
0.0001, respectively, data not shown). 
We examined the role of p27 and cyclin E protein levels in
high and low Ki-67 index patients. In the low Ki-67 index group
(89 patients) there was no difference in survival rates between
high and low p27 staining or between high and low cyclin E
staining (data not shown). In contrast, in the high Ki-67 index
group (56 patients), patients with high p27 staining showed a
better prognosis than those with low p27 staining for both
disease-free and overall survival (P = 0.0055, P = 0.0026,
respectively, Figure 4A, C). High cyclin E staining was asso-
ciated with a favourable prognosis for overall (P = 0.0022) but
not disease-free survival (P = 0.0637) in the high Ki-67 index
group (Figure 4B, D). The prognosis of patients with low
protein levels of both p27 and cyclin E and a high Ki-67 index
was extremely poor. 
Analysis of p27 and cyclin E in superficial bladder
cancer 
By comparison, which of grade, p27, cyclin E and Ki-67 has a
significant influence on disease-free survival in superficial
tumours (Ta, T1; 86 patients), p27 and Ki-67 were statistically
significant predictors by univariate (P = 0.0057, P = 0.0098,
respectively) and multivariate analysis (P = 0.0048 and P =
0.0178, respectively, Table 4). Kaplan–Meier plots revealed that
there was a significant correlation between the combination of low
expression of p27 and a high Ki-67 index and early recurrence
(P = 0.003, P = 0.0063, respectively, Figure 5B, C). 
35 of 86 patients with superficial bladder tumours suffered recur-
rence. We classified these tumours into 2 groups in order to evaluate
the roles of the alterations of expression status of p27, cyclin E, and
Ki-67 in the progression of bladder tumours (Table 4). In group A
(26 patients), although the superficial tumour recurred, the tumour
remained at a low stage, and these patients showed a better prog-
nosis. In group B (9 patients), the recurrent tumour finally invaded
the muscle layer, and the prognosis of these patients was poor. At
first operation, the Ki-67 index was higher in group B than in group
A (P = 0.0007), but no difference was found between the groups in
expression levels of p27 and cyclin E. In contrast, higher protein
levels of p27 (P = 0.0149) and cyclin E (P = 0.0165) were observed
in group A in comparison to group B at the second operation, while
the difference previously noted for Ki-67 index was no longer
apparent. The similar expression pattern of these protein levels was
found in the final operation (3–7 times). 
DISCUSSION 
In G1/S phase, the p16INK4a-cyclin D1-Cdk4/6-retinoblastoma gene
(Rb) pathway contributes greatly to tumour development (Hunter
and Pines, 1994). In bladder cancer, deletions of p16INK4a (Orlow
et al, 1999), low expression of Rb (Cordon-Cardo et al, 1992;
Logothetis et al, 1992), and overexpression of cyclin D1 (Lee et al,
Figure 1 Immunohistochemical staining using anti-p27Kip1 (left panel) and
anti-cyclin E (right panel) monoclonal antibody in papillary type, grade 1 and
pT1 bladder tumour (3 400 magnification). Left panel shows intensely brown
staining in most of the nuclei of the cancer cells, displaying high p27Kip1
protein levels. Right panel shows weakly brown staining in many of the nuclei
of the cancer cells from the same section of left panel, showing high cyclin E
protein levels 
Figure 2 Immunohistochemical staining using anti-p27Kip1 (left panel) and
anti-cyclin E (right panel) monoclonal antibody in non-papillary type, grade 3
and pT3 bladder tumour (3 400 magnification). Left panel shows very weakly
brown staining in some of the nuclei of the cancer cells, diaplaying low
p27Kip1 protein levels. Right panel shows negative reaction for anti-cyclin E
monoclonal antibody from the same section of left panel, displaying low
cyclin E protein levelsAlteration of p27 Kip1, cyclin E and Ki-67 in bladder cancer 1245
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1997; Shin et al, 1997) are involved in progression of these
tumours. p16INK4a, p21WAF/CIP1, p27, cyclin D1-Cdk4/6 complex and
cyclin E-Cdk2 complex are involved in the G1/S transition by
regulating phosphorylation of Rb (Toyoshima and Hunter, 1994).
Among these, p27 and cyclin E play a central role in the transition
from late G1 to S phase (Steeg and Abrams, 1997). Therefore, it is
possible to assess the role of p27 and cyclin E in tumour recur-
rence and progression and to define their value in predicting
survival in patients with bladder cancer. 
There is a significant inverse correlation of p27 protein levels
with grade and stage. Low p27 protein levels are associated with
poorer survival in breast (Catzavelos et al, 1997), gastric (Mori
et al, 1997), prostate (Tsihlias et al, 1998), upper uninary tract
(Kamai et al, 2000), and bladder cancer (Del Pizzo et al, 1999; Lee
et al, 1999). In addition, low protein levels of p27 were a negative
prognostic factor in lung (Esposito et al, 1997), colorectal (Loda
et al, 1997), and ovarian cancer (Masciullo et al, 1999). In the
present study, low protein levels of p27 were associated with
poorly differentiated grade, muscle and lymph node invasion, and
unfavourable prognosis. Therefore, it is likely that p27 affects
differentiation pathways and acts as a tumour suppressor gene in
different human tumours; evaluation of p27 protein levels may
indicate the biological behaviour of human tumours. 
High protein levels of cyclin E are associated with increasing
tumour grade and mortality in breast cancer (Keyomarsi et al,
1995). Since p27 levels are mainly regulated by ubiquitin-
mediated proteasome degradation, which is targeted by cyclin E-
Cdk2 phophorylation of p27 (Vlach et al, 1997), it is likely
that loss of p27 expression and high expression of cyclin E are
associated with cancer progression and unfavourable prognosis.
Low protein levels of p27 and increased protein levels of cyclin E
correlated with shortened survival in breast cancer (Porter et al,
1997). In contrast, low staining of p27 and cyclin E correlated with
poorly differentiated grade, muscle invasion, lymph node involve-
ment and poor survival in bladder cancer patients in this and
previous studies (Del Pizzo et al, 1999). There may be different
1
0.8
0.6
0.4
0.2
0
S
u
r
v
i
v
a
l
 
r
a
t
e
 A
high p27 (n=23)
low p27 (n=33)
P =0.0055
0 2 04 06 08 0
Time (months)
 C
1
0.8
0.6
0.4
0.2
0
0 2 04 06 08 0 1 0 0
Time (months)
 B D
1
0.8
0.6
0.4
0.2
0
S
u
r
v
i
v
a
l
 
r
a
t
e
1
0.8
0.6
0.4
0.2
0
high cyclin E (n=17)
low cyclin E (n=39)
P =0.0637
high cyclin E (n=17)
low cyclin E  (n=39)
P =0.0022
Time (months) Time (months)
high p27 (n=23)
low p27 (n=33)
pP
10 30 50 70
02 04 06 08 0 10 30 50 70 0 2 04 06 08 0 1 0 0
               
Figure 3 Survival curve in 145 patients with bladder cancer based on the p27 (A; Disease-free survival curve. C; Overall survival curve) and cyclin E
immunointensity (B; Disease-free survival curve. D; Overall survival curve). P value was analysed by log-rank test. The prognosis of the patients with high p27
and cyclin E staining was better than those with low p27 and cyclin E staining regulatory mechanisms in expression of these genes between
breast and bladder cancer. Del Pizzo et al (1999) suggested that
cellular down-regulation of cyclin E may be an attempt to offset
loss of p27 expression during tumour growth via a feedback inhib-
itory loop. In the present study, there was a positive relationship
between protein levels of p27 and cyclin E and a negative relation-
ship between p27 and cyclin E staining and Ki-67 index.
Furthermore, in the high Ki-67 index group whose prognosis was
poor, patients with high p27 staining showed a better prognosis
than those with low p27 staining. 
These data suggest that p27 inhibits bladder tumour prolifera-
tion and progression. Low cyclin E staining was also associated
with shorter overall survival in the high Ki-67 index group. These
findings support the data of Del Pizzo et al (1999). On the other
hand, Richter et al (2000) recently reported that cyclin E expres-
sion was significantly more frequent in pT1 than pTa tumours, but
protein levels significantly decreased from pT1 to pT2-4, and low
cyclin E expression was associated with poor overall survival in
TCC of the bladder, suggesting that cyclin E overexpression might
be characteristic to a subset of bladder cancers, especially at the
stage of early invasion. We similarly observed that protein levels
of cyclin E were higher in pTa-1 than pT2-4 (Table 1), these
decreased as cancer became invasive (Table 4). 
Superficial bladder tumours (Ta, T1) frequently recur and
progress to invasive disease (Loening et al, 1980; Heney et al,
1983). One problem in the evaluation of superficial bladder
tumours is the tendency to underdiagnose the extent of disease.
Given the problem of underdiagnosing superficial tumours, it
would be interesting to evaluate the prognostic value of p27 and
cyclin E protein in these tumours. In the current study a significant
correlation was observed between low protein levels of p27 and
decreased disease-free survival in superficial tumours, but this was
not found for cyclin E (Table 3). Similar relationship between
cyclin E expression and disease-free survival in superficial
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Figure 4 Survival curve in high Ki-67 labelling index patients based on the p27 (A; Disease-free survival curve. C; Overall survival curve) and cyclin E
(B; Disease-free survival curve. D; Overall survival curve) immunointensity. P value was analysed by log-rank test. Decreased p27 staining was associated with
decreased relapse-free survival and with increased disease-specific mortality and decreased cyclin E staining was associated with increased disease-specific
mortality tumours was reported (Richter et al, 2000). Impressively, serial
immunostaining over time showed that tumours with consistently
high protein levels of p27 and cyclin E did not progress to invasive
disease and showed a better prognosis, regardless of a high Ki-67
index (Table 4). These findings suggested that decreasing protein
levels of p27 and cyclin E and increasing Ki-67 index may be
associated with transformation of bladder tumour cells into more
aggressive cancers. Therefore, serial examination of protein levels
Alteration of p27 Kip1, cyclin E and Ki-67 in bladder cancer 1249
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Figure 5 Disease-free survival curve based on grade (A), Ki-67 (B), p27 (C) and cyclin E (D) in superficial tumours. P value was analysed by log-rank test.
High Ki-67 index and low p27 staining correlated with shortened disease-free survival
Table 3 Cox regression analysis for Grade, Ki-67, P27 and cyclin E in recurence in superficial tumours 
Variable Unfavourable /   No. of patients Analysis Relative risk 95% confidence interval P value 
favourable
characteristics
Grade 3/2/ 1 13/35/38  Univariate (U) 1.288 0.729–2.274 0.384 
Multivariate (M) 1.16 0.535–1.723 0.96 
Ki-67 high/low 16/70  U 3.289 1.333–8.115 0.0098 
M 3.586 1.247–10.313 0.0178 
p27 low/high 38/48 U 3.723 1.467–9.448 0.0057   
M 3.898 1.514–10.035 0.0048 
Cyclin E low/high 33/53  U 1.941 0.853–4.420 0.1941 
M 1.231 0.514–2.951 0.6407 1250 T Kamai et al
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of p27, cyclin E and Ki-67 have the potential to classify local
recurrence patients into either significantly elevated or reduced
risk groups. Such a classification may determine which patients
would benefit from more aggressive therapy. If protein levels of
p27 and cyclin E decrease with time, it may be preferable to
change to more aggressive treatment methods, regardless of the
Ki-67 index. 
Stage, grade and lymph node metastasis are associated with
survival, and treatment decisions for individual patients with
bladder cancer have been based on these conventional prognostic
factors. In the present study, low protein levels of p27 and cyclin E
and a high Ki-67 index were associated with poorly differentiated
grade, muscle invasion and unfavourable prognosis in bladder
cancer. Furthermore, using multivariate analysis, p27 and Ki-67
were significant covariates for disease-free survival, and Ki-67,
cyclin E, p27 and stage were factors for overall survival. These
findings suggest that p27, cyclin E and Ki-67 are independent
prognostic markers in bladder tumours. 
We did not analyse the effect of intravesical chemotherapy or
immunotherapy for superficial bladder tumours on changes in
these cell cycle-regulating proteins in the current study. We
demonstrated here that the decreasing of p27 and cyclin E is
involved in the progression of the bladder tumour. Patients under-
going intravesical chemotherapy or immunotherapy are thought to
share the same risk factors for invasive disease as those treated
with transurethral resection alone (Lamm et al, 1995; Vegt et al,
1995). Fujii et al (1998) suggested that conventional pathological
prognostic factors had a more important influence on the progres-
sion of superficial tumours than the choice of treatment. The role
of p27 and cyclin E in treated patients will be the subject of a forth-
coming study. While previous studies have not found p27 or cyclin
E gene mutations in human tumours, mutations of these genes in
bladder tumours are under investigation. 
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